Satoh, Taroh
Kato, Ken
Ura, Takashi
Hamamoto, Yasuo
Kojima, Takashi
Tsushima, Takahiro
Hironaka, Shuichi
Hara, Hiroki
Iwasa, Satoru
Muro, Kei
Yasui, Hirofumi
Minashi, Keiko
Yamaguchi, Kensei
Ohtsu, Atsushi
Doki, Yuichiro
Matsumura, Yasuhiro
Kitagawa, Yuko
Funding for this research was provided by:
Ono Pharmaceutical (00)
Bristol-Myers Squibb (00)
Article History
Received: 17 March 2021
Accepted: 4 May 2021
First Online: 16 May 2021
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent. The study protocol was approved by the institutional review board at each study site.
: Taroh Satoh received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and grants from Ono, Chugai, Yakult Honsha, Eli Lilly, Bristol-Myers Squibb, MSD, Gilead Sciences, Parexel, Daiichi Sankyo, and Astellas; honoraria from Ono, Chugai, Yakult Honsha, Eli Lilly, Bristol-Myers Squibb, and Daiichi Sankyo; and travel fee from Ono outside the submitted work. Ken Kato received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and grants from Ono, MSD, AstraZeneca, Bayer, Chugai, BeiGene, and Shionogi; honoraria from Ono and Bristol-Myers Squibb outside the submitted work. Takashi Ura, Yasuo Hamamoto, Hirofumi Yasui, and Yuichiro Doki received research funding from Ono and Bristol-Myers Squibb during the conduct of the study. Takashi Kojima received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and research funding from MSD, Astellas Amgen BioPharma, Taiho, Chugai, and Shionogi; and honoraria from Ono, Bristol-Myers Squibb, MSD, Astellas, Merck, and Oncolys BioPharma outside the submitted work. Takahiro Tsushima received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and honorarium from Ono outside the submitted work. Shuichi Hironaka received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and honoraria from Bristol-Myers Squibb, Ono, Taiho, Daiichi Sankyo, Eli Lilly, Chugai, Nippon kayaku, Tsumura, Sanofi, Merck, and AstraZeneca outside the submitted work. Hiroki Hara received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and research funding from Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Elevar Therapeutics, GSK, Incyte, Merck Biopharma, MSD, Ono, Pfizer, and Taiho; consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Eli Lilly, MSD, and Ono; and honoraria from Bayer, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, Eli Lilly, Merck Biopharma, MSD, Ono, Sanofi, Taiho, Takeda, and Yakult outside the submitted work. Satoru Iwasa received research funding from Ono, Bristol-Myers Squibb, and Pfizer during the conduct of the study; and honoraria from Ono and Bristol-Myers Squibb outside the submitted work. Kei Muro received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and research funding from Solasia, Merck Serono, Daiichi Sankyo, Parexel International, Pfizer, MSD, Amgen, Ono, Sanofi, and Taiho; consulting fees from Amgen, Ono, and AstraZeneca; and honoraria from Ono, Sanofi, Taiho, Chugai, Takeda, Eli Lilly, Bristol-Myers Squibb, and Bayer outside the submitted work. Keiko Minashi received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and research funding from MSD, Mediscience Planning, Merck Biopharma, Astellas, Taiho, and Daiichi Sankyo outside the submitted work. Kensei Yamaguchi received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and grants from Taiho, Yakult Honsha, Sanofi, Ono, and Elli Lilly; and honoraria Taiho, Chugai, Bristol-Myers Squibb, Merck Serono, Takeda, Ono, and Elli Lilly outside the submitted work. Atsushi Ohtsu received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and honorarium from Bristol-Myers Squibb outside the submitted work. Yasuhiro Matsumura is an employee and a stockholder of Ono. Yuko Kitagawa received research funding from Ono and Bristol-Myers Squibb during the conduct of the study; and grants from Takeda, Chugai, Taiho, Yakult Honsha, Asahi Kasei, Otsuka, Ono, Tsumura, EA, Astellas, Toyama Chemical, Medicon, Kaken, Eisai, Otsuka, Teijin, Nihon, and Nippon Covidien; and honoraria from Chugai, Taiho, Asahi Kasei, Otsuka, Shionogi, and Nippon Covidien outside the submitted work.